echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Nature sub-Journal of basic scientific research: anti-"AIDS" vaccine is expected to reduce the risk of rhesus monkey infection by 79%

    Nature sub-Journal of basic scientific research: anti-"AIDS" vaccine is expected to reduce the risk of rhesus monkey infection by 79%

    • Last Update: 2021-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Speaking of the three words "AIDS", I believe everyone is familiar with it.
    December 1 this year is the 34th "World AIDS Day" with the theme "Life First, Ending AIDS, Equality of Health"
    .


    AIDS is also called Acquired Immune Deficiency Syndrome.


    Source: Nature Medicine Nature Medicine research results show that compared with the unvaccinated control group, the probability of rhesus monkeys infected with Simian-Human Immunodeficiency Virus (SHIV) after initial vaccination and repeated booster shots Reduced by 79% .
    In addition, the new mRNA vaccine is highly safe, and can simultaneously activate humoral immunity and cellular immunity for epidemic prevention .
    And unvaccinated control group comparison, the initial vaccination and inoculation strengthen rhesus monkeys after repeated needle infection apes - the probability of human immunodeficiency virus (SHIV) reduced by 79% of the new vaccine safety than mRNA High, it can start humoral immunity and cellular immunity at the same time for epidemic prevention .
    The principle of the new HIV vaccine is similar to that of the mRNA new coronavirus vaccine .
    The researchers encapsulated Env (equivalent to the S protein of SARS-CoV-2) and the group-specific antigen protein Gag, which encodes the key HIV protein envelope glycoprotein, in lipid nanoparticles (LNP) to produce virus-like particles in the body (VLP) .


     Env-Gag VLP expressed by three representative mRNAs The Env-Gag VLP expressed by three representative mRNAs was tested on rhesus monkeys and then evaluated the effectiveness of the env-gag mRNA vaccine that produces VLP in rhesus monkeys.
    Immunogenicity and efficacy, and challenged with live SIV carrying HIV-1 Env


    Induction of neutralizing antibodies in immunized rhesus monkeys over time

    Induction of neutralizing antibodies in immunized rhesus monkeys over time.


    Next, virus-specific T cell responses were tested against the two viral antigens expressed by the vaccine (ie HIV-1 Env and SIV Gag) at two time points: week 27 after the completion of the autologous phase And the 60th week .
    The multifunctional Env-specific CD4+ T cell response was already detectable at the 27th week, but it was significantly enhanced in all animals at the 60th week .
    It is worth noting that the versatility of CD4+ T cells increased significantly at the 60th week.
    Nearly 50% of the responding cells co-express three or more cytokines, which is consistent with the strong T cell helper activity that triggers antibody production .


    Induction of Env-specific T cell responses in immunized rhesus monkeys

    Induction of Env-specific T cell responses in immunized macaques, the main researcher, Dr.


    Lusso, said that Env translated from mRNA is very similar to Env in natural HIV, and the VLP used in the experiment can display multiple HIV envelope proteins, which is induced by vaccines.
    The immune response process is very similar to the natural infection process


    End

    Reference materials:

    Reference materials:

    [1]https://doi.


    org/10.
    1038/s41591-021-01574-5

    [1]https://doi.
    org/10.
    1038/s41591-021-01574-5 [2]https://mp.
    weixin.
    qq.
    com/s/rahN784ztvKjYqkEjkZR7w Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.